Terms: = Ovarian cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Staging
5 results:
1. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract] [Full Text] [Related]
2. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract] [Full Text] [Related]
3. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis.
Zhang W; Yang HC; Wang Q; Yang ZJ; Chen H; Wang SM; Pan ZM; Tang BJ; Li QQ; Li L
Anticancer Res; 2011 Oct; 31(10):3423-8. PubMed ID: 21965756
[TBL] [Abstract] [Full Text] [Related]
4. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.
Barak F; Milgrom R; Laitman Y; Gemer O; Rabinovich A; Piura B; Anteby E; Baruch GB; Korach J; Friedman E
Gynecol Oncol; 2010 Dec; 119(3):511-5. PubMed ID: 20850175
[TBL] [Abstract] [Full Text] [Related]
5. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract] [Full Text] [Related]
